Compare Philip Morris International Inc. (PM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs GeneDx Holdings Corp — how do they compare? Philip Morris International Inc. trades at $185.71 (market cap $287.92B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Philip Morris International Inc. is far larger — about 112.5× GeneDx Holdings Corp's market cap, and Philip Morris International Inc. pays a 3.18% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| PM | WGS | |
|---|---|---|
Market Cap | $287.92B | $2.56B |
Sector | Consumer Staples | Technology |
52-Week High | $200.17 | $167.51 |
52-Week Low | $144.33 | $34.51 |
Enterprise Value | $331.04B | $2.60B |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $185.71, up 1.74% with a bearish technical signal. Recent earnings show beats in Q1 and Q2 2026, but the company cut its 2026 profit forecast due to a $500 million impairment and cost pressures. Fundamentals remain strong with a 25.56% net margin and $11.35B net income in 2025, though high debt and illicit market growth in Europe pose risks. Analyst consensus is bullish with a $211.17 price target.
The stock offers a solid dividend and brand strength via IQOS, but faces headwinds from currency swings, energy costs, and regulatory challenges. Upside depends on execution amid margin pressure, with the current price near the low end of analyst targets suggesting cautious optimism for long-term investors.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
